44 Matching Annotations
  1. Last 7 days
    1. 125F668823802361389153289>300018,40050231Eosinophils 17%, fungal scrapes—positive

      Case#: 12, M, 5 y.o., Ethnicity: Indian.

      CasePresentingHPOs: HP:0001945 (Fever), HP:0001824 (Weight loss), HP:0002716 (Lymphadenopathy/FHL), HP:0003212 (Increased circulating IgE level), HP:0002716 (Lymphadenopathy), HP:0009098 (Chronic oral candidiasis), HP:0002841 (Recurrent fungal infections), HP:0032326 (Methicillin-resistant Staphylococcus aureus infection), HP:0020271 (Increased lymph-node eosinophils), HP:0100827 (Lymphocytosis), HP:0003237 (Increased circulating IgG level), HP:0002090 (Pneumonia)

      CaseHPOFreeText: Eosinophils 17%, fungal scrapes—positive. Methicillin-resistant Staphylococcus aureus pneumonia, oral candidiasis/Hyper IgE.

      Suspected recurring pneumonia.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: N/A.

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: Sanger sequencing and NGS targeting a customized panel of genes.

      Variant: NM_005026.5:c.2296G>A.

      ClinVar: 846790.

      CAID: CA577485.

      gnomAD: 0.00001611. https://gnomad.broadinstitute.org/variant/1-9722305-G-A?dataset=gnomad_r4.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    1. P01FGerman4556c.109+1 G>TReduced0.88Pathogenic22.5Pathogenic[4]10.42Mildly affectedAlive

      Case#: P01, Female, clinical diagnosis at the age of 45, genetic diagnosis at the age of 56, German, alive at the time of article's publication

      DiseaseAssertion: Patient is classified as "Mildly affected" based on a CHAI score of 10.42%.

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.109+1G>T

      ClinVar ID: 161113

      gnomAD: This variant was not found in any gnomAD version.

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    2. P02FFinnishukuk*c.109+2 T>AReduced––45.9PathogenicukNANAAlive

      Case#: P02, Female, the age of clinical and genetic diagnosis: Unknown, Finnish, alive at the time of article's publication

      DiseaseAssertion: N/A

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NC_000002.12:g.203868053T>A

      ClinVar ID:

      CAID: CA350138070

      gnomAD: not found in any gnomAD version.

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    3. P03Mukukuk*G52DReduced––17.2PathogenicukNANAAlive

      Case#: P03, Male, Age: N/A, ethnicity: N/A, Alive at the time of article's publication

      DiseaseAssertion: N/A

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.155G>A (p.Gly52Asp)

      ClinVar ID: 871301

      gnomAD: not found in any gnomAD version.

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    4. P04Mukuk71.4A54TReduced2.04Pathogenic49.8Pathogenic[9]NANADead

      Case#: P04, male, genetic diagnosis at the age of 71.4, ethnicity: N/A, Dead at the time of article's publication

      DiseaseAssertion: N/A

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.160G>A (p.Ala54Thr)

      ClinVar ID: 430905

      gnomAD: not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    5. P05MukukukR70WReduced––30.6Pathogenic[4]NANAAlive

      Case#: P05, Male, age: n/a, ethnicity:n/a, alive at the time of publication

      DiseaseAssertion: N/A

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: <br /> NM_005214.5(CTLA4):c.208C>T (p.Arg70Trp)

      ClinVar ID: 161114

      gnomAD: 6.195e-7 https://gnomad.broadinstitute.org/variant/2-203870684-C-T?dataset=gnomad_r4

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    6. P06FGerman52uk*T72PReduced2.39Pathogenic––uk47.37Severely affectedAlive

      Case#: P06. Female, German, 52 years old at the time of clinical diagnosis, Alive at the time of publication

      DiseaseAssertion: classified as "Severely affected" based on a CHAI score of 47.37%

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.214A>C (p.Thr72Pro)

      ClinVar ID: 546886

      gnomAD: not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    7. P07MGerman1824.2R75QReduced7.29Pathogenic––[5]17.65Mildly affectedAlive

      Case#: P07, Male, German, 18 years old at the time of clinical diagnosis and 24.2 years old at the time of genetic diagnosis, alive at the time of publication

      DiseaseAssertion: Mildly affected based on a CHAI score of 17.65%

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: <br /> NM_005214.5(CTLA4):c.224G>A (p.Arg75Gln)

      ClinVar ID: 943305

      gnomAD: 0.000008673

      https://gnomad.broadinstitute.org/variant/2-203870700-G-A?dataset=gnomad_r4

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    8. P08FCanadianukukA86VReduced9.18Pathogenic60.8Non-pathogenic[5]NANAAlive

      Case#: P08, Female, Canadian, age: n/a, alive at the time of publication

      DiseaseAssertion: N/A

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.257C>T (p.Ala86Val)

      ClinVar ID: 661941

      gnomAD: 0.00001859

      https://gnomad.broadinstitute.org/variant/2-203870733-C-T?dataset=gnomad_r4

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    9. P09Mukukuk*Y89HNormal––58.5Non-pathogenicukNANAAlive

      Case#: P09, Male, age: n/a, ethnicity: n/a, alive at the time of publication

      DiseaseAssertion: n/a

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.265T>C (p.Tyr89His)

      ClinVar ID: 1391402

      gnomAD: 0.000003717 https://gnomad.broadinstitute.org/variant/2-203870741-T-C?dataset=gnomad_r4

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    10. P10FGerman2425G109EReduced7.58Pathogenic––[5]33.33Severely affectedAlive

      Case#: P10, Female, German, 24 years old at the time of clinical diagnosis, 25 years old at the time of genetic diagnosis, alive at the time of publication

      DiseaseAssertion: Severely affected based on a CHAI score of 33.33%

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.326G>A (p.Gly109Glu)

      ClinVar ID: 542071

      gnomAD: 0.0002354 https://gnomad.broadinstitute.org/variant/2-203870802-G-A?dataset=gnomad_r4

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    11. P11FGermanukukG109ENormal5.11Pathogenic75.8Non-pathogenic[12]18.75Severely affectedAlive

      Case#: P11, Female, German, age: n/a, alive at the time of publication

      DiseaseAssertion: Severely affected based on a CHAI score of 18.75%

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.326G>A (p.Gly109Glu)

      ClinVar ID: 542071

      gnomAD: 0.0002354 https://gnomad.broadinstitute.org/variant/2-203870802-G-A?dataset=gnomad_r4

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    12. P12ukukukukG109ENormal––67.3Non-pathogenicukNANAuk

      Case#: P12, sex: n/a, age: n/a, ethnicity: n/a

      DiseaseAssertion: n/a

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.326G>A (p.Gly109Glu)

      ClinVar ID: 542071

      gnomAD: 0.0002354 https://gnomad.broadinstitute.org/variant/2-203870802-G-A?dataset=gnomad_r4

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    13. P13MGerman3840.6L119RReduced6.72Pathogenic50.3Pathogenic[12]52.38Severely affectedAlive

      Case#: P13, Male, German, 38 years old at the time of clinical diagnosis, 40.6 yeras old at the time of genetic diagnosis, alive at the time of publication

      DiseaseAssertion: severly affected based on a CHAI score of 52.38%

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: ENST00000295854.10:c.356T>G

      ClinVar ID: not found

      CAID:CA350138616

      gnomAD: not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    14. P14FCzechuk36M123Ifs*15Reduced4.16Pathogenic––[9]NANADead

      Case#: P14, Female, Czech, 36 years old at the time of genetic diagnosis, daed at the time of publication

      DiseaseAssertion: n/a

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: unregistered variant - without the bp change we can't confidently assert this variant at this time but it is possible it is CA2953901753

      ClinVar ID: n/a

      gnomAD: not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    15. P15Fukukuk*I128MNormal––70.7Non-pathogenicukNANAAlive

      Case#: P15, female, age: n/a, ethnicity: n/a, alive at the time of publication

      DiseaseAssertion: n/a

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.384C>G (p.Ile128Met)

      ClinVar ID: 662956

      gnomAD: 0.000006814

      https://gnomad.broadinstitute.org/variant/2-203870860-C-G?dataset=gnomad_r4

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    16. P16MGermanukuk*V131AReduced3.28Pathogenic––uk45.83Severely affectedAlive

      Case#: P16, male, german, age: n/a, alive at the time of publication

      DiseaseAssertion: Severely affected based on a CHAI score of 45.83%

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.392T>C (p.Val131Ala)

      ClinVar ID: 624171

      gnomAD: Not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    17. P17MBelgianuk40P136LReduced3.23Pathogenic54.2Pathogenic[9]NANAAlive

      Case#: P17, Male, Belgian, 40 years at the time of genetic diagnosis, alive at the time of publication

      DiseaseAssertion: n/a

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.407C>T (p.Pro136Leu)

      ClinVar ID: 1711524

      gnomAD: not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    18. P18FGermanuk32.3Y139CNormal––55.8Pathogenic[10]11.11Mildly affectedAlive

      Case#: P18, Female, German, 32.2 years old at the time of genetic diagnosis, alive at the time of publication

      DiseaseAssertion: Mildly affected based on a CHAI score of 11.11%

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.416A>G (p.Tyr139Cys)

      ClinVar ID: 623475

      gnomAD: not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    19. P22FGermanukuk*L163Sfs*24Reduced––37.2Pathogenicuk42.86Severely affectedAlive

      Case#: P22, Female, German, age: n/a , alive at the time of publication

      DiseaseAssertion: Severely affected based on a CHAI score of 42.86%

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: ENSP00000497102.1:p.Leu163Ser

      ClinVar ID:

      CAID: PA2850594025

      gnomAD: Not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    20. P21FAmericanukuk*P156LReduced––36.7PathogenicukNANAAlive

      Case#: P21, female, American, age: n/a, alive at the time of publication

      DiseaseAssertion: n/a

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.467C>T (p.Pro156Leu)

      ClinVar ID: 1035066

      gnomAD: 0.00002292 https://gnomad.broadinstitute.org/variant/2-203871387-C-T?dataset=gnomad_r4

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    21. P19FItalianukukN145SNormal16.9Non-pathogenic––[9]NANAAlive

      Case#: P19, Female, Italian, age: n/a, alive at the time of diagnosis

      DiseaseAssertion: n/a

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: ENST00000295854.10:c.434A>G

      ClinVar ID:

      CAID: CA350138791

      gnomAD: 6.197e-7 https://gnomad.broadinstitute.org/variant/2-203870910-A-G?dataset=gnomad_r4

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    22. P20MGerman2222.7T147Rfs*8Reduced––30.7Pathogenic[12]42.11Severely affectedDead

      Case#: P20, male, German, 22 years old at the time of clinical diagnosis, 22.7 years old at the time of genetic diagnosis, dead at the time of publication

      DiseaseAssertion: Severely affected based on a CHAI score of 42.11%

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NP_001032720.1:p.Thr147Arg

      ClinVar ID:

      CAID: PA2850594024

      gnomAD: Not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    1. P1

      Case#: P1, M, Age of Report: N/A, Ethnicity: N/A.

      CasePresentingHPOs: HP:0000490 (Deeply set eye/Ocular depression), HP:0000680 (Delayed eruption of primary teeth/Teeth delay), HP:0000540 (Hypermetropia/Hyperopia), HP:0000483 (Astigmatism), HP:0007485 (Absence of subcutaneous fat/Lack of subcutaneous fat), HP:0000831 (Insulin-resistant diabetes mellitus), HP:0000325 (Triangular face/Facial dysmorphim Triangular shape), HP:0000430 (Underdeveloped nasal alae/thin alae nasi), HP:0000331 (Short chin/Small chin), HP:0000369 (Low-set ears), HP:0012371 (Hyperplasia of midface/Mild midface hypoplasia), HP:0000347 (Micrognathia), HP:0100678 (Premature skin wrinkling/Thin, wrinkled skin), HP:0001256 (Intellectual disability, mild/Mild impairment),

      CaseHPOFreeText: Proband was noted to have readily visible veins and delayed bone age.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: N/A.

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES.

      Variant: NM_181523.3:c.1615_1617del (p.Ile539del).

      ClinVar: 60761.

      CAID: CA344796.

      gnomAD: N/A.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    2. P2

      Case#: P2, M, Age of Report: N/A, Ethnicity: N/A.

      CasePresentingHPOs: HP:0000490 (Deeply set eye/Ocular depression), HP:0000680 (Delayed eruption of primary teeth/Teeth delay), HP:0007485 (Absence of subcutaneous fat/Lack of subcutaneous fat), HP:0000831 (Insulin-resistant diabetes mellitus), HP:0000325 (Triangular face/Facial dysmorphim Triangular shape), HP:0000430 (Underdeveloped nasal alae/thin alae nasi), HP:0000331 (Short chin/Small chin), HP:0000369 (Low-set ears), HP:0012371 (Hyperplasia of midface/Mild midface hypoplasia), HP:0000347 (Micrognathia), HP:0100678 (Premature skin wrinkling/Thin, wrinkled skin), HP:0001256 (Intellectual disability, mild/Mild impairment),

      CaseHPOFreeText: Proband was noted to have readily visible veins and delayed bone age.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: N/A..

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES.

      Variant: NM_181523.3:c.1465G>A (p.Glu489Lys).

      ClinVar: 60762.

      CAID: CA344798.

      gnomAD: N/A.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    3. P3

      Case#: P3, F, Age of Report: N/A, Ethnicity: N/A.

      CasePresentingHPOs: HP:0001382 (Joint hypermobility/Hyperextensibility of joints), HP:0000490 (Deeply set eye/Ocular depression), HP:0000558 (Rieger anomaly), HP:0000680 (Delayed eruption of primary teeth/Teeth delay), HP:0000540 (Hypermetropia/Hyperopia), HP:0000483 (Astigmatism), HP:0000565 (Esotropia), HP:0007485 (Absence of subcutaneous fat/Lack of subcutaneous fat), HP:0000831 (Insulin-resistant diabetes mellitus), HP:0000325 (Triangular face/Facial dysmorphim Triangular shape), HP:0011220 (Prominent forehead), HP:0000430 (Underdeveloped nasal alae/thin alae nasi), HP:0000331 (Short chin/Small chin), HP:0000369 (Low-set ears), HP:0012371 (Hyperplasia of midface/Mild midface hypoplasia), HP:0000347 (Micrognathia), HP:0000138 (Ovarian cyst), HP:0001256 (Intellectual disability, mild/Mild impairment), HP:0003100 (Slender long bone/Gracile long bones)

      CaseHPOFreeText: Proband was noted to have delayed bone age and mild impairment and/or speech delay

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: N/A..

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES.

      Variant: NM_181523.3:c.1945C>T (p.Arg649Trp).

      ClinVar: 60763.

      CAID: CA344799.

      gnomAD: N/A.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    4. P4

      Case#: P4, M, Age of Report: N/A, Ethnicity: N/A.

      CasePresentingHPOs: HP:0004322 (Short stature), HP:0004325 (Decreased body weight), HP:0040195 (Decreased head circumference), HP:0000490 (Deeply set eye/Ocular depression), HP:0000680 (Delayed eruption of primary teeth/Teeth delay), HP:0000540 (Hypermetropia/Hyperopia), HP:0007485 (Absence of subcutaneous fat/Lack of subcutaneous fat), HP:0000325 (Triangular face/Facial dysmorphim Triangular shape), HP:0011220 (Prominent forehead), HP:0000430 (Underdeveloped nasal alae/thin alae nasi), HP:0000331 (Short chin/Small chin), HP:0000369 (Low-set ears), HP:0012371 (Hyperplasia of midface/Mild midface hypoplasia), HP:0000347 (Micrognathia), HP:0100678 (Premature skin wrinkling/Thin, wrinkled skin),

      CaseHPOFreeText: Proband was noted to readily visible veins, normal mental development.

      Proband was not evaluated for insulin resistance, ovarian cysts, delayed bone age or gracile long bones.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: Proband was noted to not have hyperextensibility of joints, inguinal hernia, Rieger anomaly, astigmatism, myopia, esotropia, diabetes, frequent illnesses, mild impairment and/or speech delay.

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES.

      Variant: NM_181523.3:c.1945C>T (p.Arg649Trp).

      ClinVar: 60763.

      CAID: CA344799.

      gnomAD: N/A.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    5. P5

      Case#: P5, F, Age of Report: N/A, Ethnicity: N/A.

      CasePresentingHPOs: HP:0001382 (Joint hypermobility/Hyperextensibility of joints), HP:0000490 (Deeply set eye/Ocular depression), HP:0000558 (Rieger anomaly), HP:0000680 (Delayed eruption of primary teeth/Teeth delay), HP:0000545 (Myopia), HP:0007485 (Absence of subcutaneous fat/Lack of subcutaneous fat), HP:0000831 (Insulin-resistant diabetes mellitus), HP:0000325 (Triangular face/Facial dysmorphim Triangular shape), HP:0011220 (Prominent forehead), HP:0000430 (Underdeveloped nasal alae/thin alae nasi), HP:0000331 (Short chin/Small chin), HP:0000369 (Low-set ears), HP:0012371 (Hyperplasia of midface/Mild midface hypoplasia), HP:0000347 (Micrognathia),

      CaseHPOFreeText: Proband was noted to have insulin resistance, frequent illnesses, ovarian cysts, normal mental development,

      Proband was not evaluated for delayed bone age or gracile long bones.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: Proband was noted to not have inguinal hernia, hyperopia, astigmatism, esotropia, thin, wrinkled skin, readily visible veins, mild impairment and/or speech delay.

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES.

      Variant: NM_181523.3:c.1945C>T (p.Arg649Trp).

      ClinVar: 60763.

      CAID: CA344799.

      gnomAD: N/A.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    6. P6

      Case#: P6, M, Age of Report: N/A, Ethnicity: N/A.

      CasePresentingHPOs: HP:0000490 (Deeply set eye/Ocular depression), HP:0000325 (Triangular face/Facial dysmorphim Triangular shape), HP:0011220 (Prominent forehead), HP:0000430 (Underdeveloped nasal alae/thin alae nasi), HP:0000331 (Short chin/Small chin), HP:0000369 (Low-set ears), HP:0012371 (Hyperplasia of midface/Mild midface hypoplasia), (Micrognathia),

      CaseHPOFreeText: Proband was not evaluated for inguinal hernia, Rieger anomaly, teeth delay, hyperopia, astigmatism, myopia, esotropia, lack of subcutaneous fat, insulin resistance, diabetes, thin, wrinkled skin, readily visible veins, frequent illnesses, ovarian cysts, normal mental development, mild impairment and/or speech delay, delayed bone age or gracile long bones.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: Proband was noted to not have hyperextensibility of joints,

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES.

      Variant: NM_181523.3:c.1945C>T (p.Arg649Trp).

      ClinVar: 60763.

      CAID: CA344799.

      gnomAD: N/A.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    7. P7

      Case#: P7, F, Age of Report: N/A, Ethnicity: N/A.

      CasePresentingHPOs: HP:0000680 (Delayed eruption of primary teeth/Teeth delay), HP:0000483 (Astigmatism), HP:0007485 (Absence of subcutaneous fat/Lack of subcutaneous fat), HP:0000831 (Insulin-resistant diabetes mellitus), HP:0011220 (Prominent forehead), HP:0000430 (Underdeveloped nasal alae/thin alae nasi), HP:0000331 (Short chin/Small chin), HP:0000369 (Low-set ears), HP:0000347 (Micrognathia),

      CaseHPOFreeText: : Proband was noted to have insulin resistance, ovarian cysts, normal mental development,

      Proband was not evaluated for hyperextensibility of joints, ocular depression, hyperopia, myopia, esotropia, Triangular face, Mild midface hypoplasia, frequent illnesses, delayed bone age or gracile long bones.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: Proband was noted to not have inguinal hernia, Rieger anomaly, thin, wrinkled skin, readily visible veins, mild impairment and/or speech delay,

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES.

      Variant: NM_181523.3:c.1945C>T (p.Arg649Trp).

      ClinVar: 60763.

      CAID: CA344799.

      gnomAD: N/A.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    8. P8

      Case#: P8, F, Age of Report: N/A, Ethnicity: N/A.

      CasePresentingHPOs: HP:0007485 (Absence of subcutaneous fat/Lack of subcutaneous fat), HP:0000831 (Insulin-resistant diabetes mellitus), HP:0000325 (Triangular face/Facial dysmorphim Triangular shape), HP:0011220 (Prominent forehead), HP:0000430 (Underdeveloped nasal alae/thin alae nasi), HP:0000331 (Short chin/Small chin), HP:0000369 (Low-set ears), HP:0012371 (Hyperplasia of midface/Mild midface hypoplasia), HP:0000347 (Micrognathia),

      CaseHPOFreeText: Proband was noted to have insulin resistance, thin, wrinkled skin, readily visible veins, frequent illnesses, normal mental development,

      Proband was not evaluated for hyperextensibility of joints, teeth delay, hyperopia, astigmatism, myopia, esotropia, ovarian cysts, delayed bone age or gracile long bones.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: Proband was noted to not have inguinal hernia, Rieger anomaly, mild impairment and/or speech delay.

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES.

      Variant: NM_181523.3:c.1943dup (p.Arg649ProfsTer5).

      ClinVar: 60764.

      CAID: CA344800.

      gnomAD: N/A.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    9. P9

      Case#: P9, M, Age of Report: N/A, Ethnicity: N/A.

      CasePresentingHPOs: HP:0004325 (Decreased body weight), HP:0007485 (Absence of subcutaneous fat/Lack of subcutaneous fat), HP:0000831 (Insulin-resistant diabetes mellitus), HP:0000325 (Triangular face/Facial dysmorphim Triangular shape), HP:0000430 (Underdeveloped nasal alae/thin alae nasi), HP:0000331 (Short chin/Small chin), HP:0000369 (Low-set ears), HP:0000347 (Micrognathia),

      CaseHPOFreeText: Proband was noted to have insulin resistance, normal mental development, mild impairment and/or speech delay,

      Proband was not evaluated for height/length, occipitofrontal circumference, hyperextensibility of joints, teeth delay, hyperopia, astigmatism, myopia, esotropia, thin, wrinkled skin, readily visible veins, frequent illnesses, ovarian cysts, delayed bone age or gracile long bones.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: Proband was noted to not have inguinal hernia, ocular depression, Rieger anomaly, Prominent forehead, Mild midface hypoplasia,

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES.

      Variant: NM_181523.3:c.1892G>A (p.Arg631Gln).

      ClinVar: 126459.

      CAID: CA347796.

      gnomAD: N/A.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    1. 14-year old female index patient

      Case#: 14-year old female index patient, F, Age of Report:, Ethnicity: Austrian.

      CasePresentingHPOs: HP:0001252 (Hypotonia), HP:0001945 (Fever), HP:0025297 (Prolonged), HP:0001873 (Thrombocytopenia), HP:0002155 (Hypertriglyceridemia), HP:0025435 (Increased circulating lactate dehydrogenase concentration/increased lactate dehydrogenase), HP:0003281 (Increased circulating ferritin concentration/markedly elevated ferritin), HP:0012156 (Hemophagocytosis),

      CaseHPOFreeText: Here we investigated a 14-year old female index patient, born to non-consanguineous healthy Austrian parents, who was hospitalized with severe hypotonia and prolonged fever. She had neither lymphadenopathy nor hepatosplenomegaly, and no infectious agent was found. Initial laboratory findings showed a mild thrombocytopenia, hypertriglyceridemia, increased lactate dehydrogenase (LDH) and markedly elevated ferritin (Table 1 and Figure 1A), prompting work up for hemophagocytic lymphohistiocytosis (HLH). Hemophagocytosis was indeed visible in the bone marrow aspirate (Figure 1B). Soluble CD25 was mildly elevated at 2204 U mL-1 (Table 1) but below the levels typically seen in HLH.6 NK-cell activity as measured by CD107a expression upon stimulation was in the low normal range in the initial diagnostic (Table 1). The presence of fever, hypertriglyceridemia, hyperferritinemia and hemophagocytosis, did not allow the diagnosis of HLH, but gave evidence of macrophage activation in the context of a hyperferritinemic inflammatory syndrome (Table 1).6We initiated treatment with dexamethasone, leading to clinical improvement and normalization of LDH and ferritin levels. Tapering of dexamethasone resulted in clinical deterioration and rise in ferritin (Figure 1A), and was accompanied by the development of autoimmune neutropenia as documented by HNA-1b antibodies. As the disease was distinct from classical HLH,6 we decided to treat the patient with recombinant human anti-IL-1β (Anakinra, 100 mg twice daily) in combination with dexamethasone, rather than using the etoposide-based HLH-94 protocol. We discontinued dexamethasone treatment after eight weeks and, one month later, reduced the Anakinra dose to a maintenance dose of 100 mg daily. The patient has remained clinically stable and is currently receiving Anakinra (decreased to 60 mg once daily) without any inflammatory manifestations. Immunological characterization of patient peripheral blood in the asymptomatic phase after ceasing dexamethasone revealed reduced absolute natural killer (NK)-cell counts and low frequency of monocytes, and slightly low absolute lymphocyte counts (Table 1)..

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: She had neither lymphadenopathy nor hepatosplenomegaly, and no infectious agent was found.

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES.

      Variant: Variant 1: NM_001282426.2:c.145C>A (p.Arg49Ser) . Variant 2: NM_001282426.2:c.3254A>G (p.Asn1085Ser).

      ClinVar: Variant 1: 1675220. Variant 2: 1675219.

      CAID: Variant 1: CA4429087. Variant 2: CA368817268.

      gnomAD: Variant 1: Frequency: 0.001519. Link: https://gnomad.broadinstitute.org/variant/chr7-106867706-C-A?dataset=gnomad_r4. Variant 2: N/A.

      VariantEvidence: N/A.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    1. A.1

      Case#: A.1, F, Age of Report: 9 y.o., Ethnicity: European-American.

      CasePresentingHPOs: HP:0012378 (Fatigue), HP:0001878 (Hemolytic anemia), HP:0006510 (Chronic pulmonary obstruction/early obstructive pulmonary impairment), HP:0003651 (Foam cells), HP:0004313 (Decreased circulating antibody concentration/Hypogammaglobulinemia), HP:0001873 (Thrombocytopenia), HP:0001888 (Lymphopenia), HP:0001880 (Eosinophilia), HP:0100721 (Mediastinal lymphadenopathy), HP:0034388 (Hilar lymph node enlargement), HP:0001744 (Splenomegaly), HP:0004387 (Enterocolitis), HP:0002014 (Diarrhea), HP:0002027 (Abdominal pain), HP:0002583 (Colitis), HP:0005425 (Recurrent sinopulmonary infections), HP:0410018 (Recurrent ear infections), HP:0001581 (Recurrent skin infections), HP:0000010 (Recurrent urinary tract infections), HP:0001742 (Nasal congestion), HP:0011010 (Chronic), HP:0000964 (Eczematoid dermatitis/Eczema),

      CaseHPOFreeText: A female patient (hereafter called A.1) from a European-American family presented at nine years of age with fatigue and hemolytic anemia followed by early obstructive pulmonary impairment. A subsequent chest CT scan revealed bilateral nodular infiltrates and areas of patchy, peripheral-basal consolidation in lungs, and histological examination revealed a pattern of interstitial CD3+ lymphocytic infiltration, foamy histiocytes, scattered noncaseating granulomas, and luminal obstruction initially characterized as cryptogenic organizing pneumonia (Fig. 1a–b). Further follow up and analysis revealed clinical progression to hypogammaglobulinemia, thrombocytopenia, various lymphopenias, eosinophilia, mediastinal and hilar lymphadenopathy, and splenomegaly (Table 1). More recently, at sixteen years of age, patient A.1 developed enterocolitis with diarrhea and abdominal pain. Histological assessment of gut tissue revealed interstitial infiltrate of more than 25 CD3+ lymphocytes per 100 epithelial cells (Fig. 1b, bottom). Episodes of pneumonitis and colitis continue to recur intermittently, have an apparent noninfectious etiology (with separate incidences of infectious colitis), and respond to pulse doses of corticosteroids and steroid-sparing measures including mycophenolate mofetil.

      The childhood of patient A.1 was remarkable for recurrent sinopulmonary, ear, skin, and urinary tract infections (commonly with S. aureus), chronic nasal congestion, and eczema. Additional episodes of colitis were sometimes associated with stool cultures positive for C. difficile and Salmonella. Vaccination responses were protective for tetanus, borderline protective for diphtheria, and protective for 4 of 23 pneumococcal strains. Warm autoimmune hemolytic anemia at nine years of age (preceding the initial pneumonitis by several months) was treated with steroids and blood transfusions; a recurrence of autoimmune cytopenias at seventeen years prompted CD20+ B cell depletion with rituximab. Patient A.1 is currently treated with immunoglobulin replacement therapy to restore humoral protection and mycophenolate mofetil to suppress inflammation.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: N/A.

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: WES and Sanger.

      Variant: NM_001282426.2:c.3062G>C (p.Arg1021Pro).

      ClinVar: 1675218.

      CAID: CA164129242.

      gnomAD: Frequency: 0.00002988. Link: https://gnomad.broadinstitute.org/variant/chr7-106905140-G-C?dataset=gnomad_r4.

      VariantEvidence: N/A.

      CaseAddInfo: Patient A.1 inherited an allele from her healthy mother in whom a single base-pair deletion causes a frameshift beginning at R982 of p110γ, and an allele from her healthy father in whom a missense mutation results in an R1021P amino acid substitution in the kinase domain.

      CasePMIDs: N/A.

    1. 15-year-old female

      Case#: 15-year-old female, F, Age of Report: 15 y.o., Ethnicity: From China.

      CasePresentingHPOs: HP:0001511 (Intrauterine growth retardation/Intrauterine growth restriction), HP:0004322 (Short stature), HP:0000684 (Delayed eruption of teeth/teething delay), HP:0000858 (Irregular menstruation/irregular menstrual cycle), HP:0001007 (Hirsutism), HP:0000820 (Abnormality of the thyroid gland/thyroid disease), HP:0005328 (Progeroid facial appearance/Progeroid facial appearance), HP:0000545 (Myopia), HP:0000678 (Dental crowding/overcrowded teeth), HP:0000855 (Insulin resistance)

      CaseHPOFreeText: Proband was noted to have "characteristic facial gestalts/"characteristic facial dysmorphim", low weight at birth,

      The proband was admitted to our department due to irregular menstrual cycle and hirsutism with short stature, who had a history of intrauterine growth restriction and presented with short stature, teething delay, characteristic facial gestalts, hirsutism, and thyroid disease. Whole-exome sequencing and Sanger sequencing revealed c.1960C > T, a novel de novo nonsense mutation, leading to the termination of protein translation (p. Gln654*).

      This is the first case report of SHORT syndrome complicated with thyroid disease in China, identifying a novel de novo heterozygous nonsense mutation in PIK3R1 gene (p. Gln654*).

      The phenotypes are mildly different from other cases previously described in the literature, in which our patient presents with lipoatrophy, facial feature, and first reported thyroid disease. Thyroid disease may be a new clinical symptom of patients with SHORT syndrome.

      The patient was a girl born to a physically healthy and non-consanguineous couple by spontaneous delivery at the 37th week. Birth weight was 2150 g (− 3.39SD) and birth length was 44 cm (− 3.41SD), indicating that the patient had intrauterine growth restriction (IUGR). The proband also had teething delay, getting the first tooth at 1 year old. During childhood, the patient was bothered by short stature. Psychomotor and speech development was normal. The height of proband’s father and mother was 168 cm and 155 cm respectively. The patient also had a healthy 20-month-old brother.

      At the age of 15 years and 4 months, the proband was referred to our department due to irregular menstrual cycle and hirsutism with a height of 149 cm (− 2.04SD), weight of 43 kg (− 1.22SD) and body mass index (BMI) of 19.4 kg/m2. The height of the proband had remained 149 cm, ever since 13 years old. Physical examination showed a triangular-shaped face, small chin, large low-set ears, thin lip, downturned mouth, obvious beard and bushy eyebrows (Fig. 1a,b,c,d). Oral examination showed overcrowded and irregular teeth, hypodontia, and severe dental caries (Fig. 1g). Pubertal development was assessed according to the Tanner stage, with pubic hair at PH5 stage and breast at B2 stage. The second phalanx of little finger in the left hand was short and thicken, which was confirmed with X-ray (Fig. 1e,f). Ultrasound of neck showed diffuse thyroid disease. Ultrasound biomicroscopy of the eyes, examination of ocular fundus, abdominal ultrasound, reproductive system ultrasound, and chest X-ray were normal. The cranial magnetic resonance imaging (MRI) indicated a small posterior pituitary.

      Not evaluated on the proband: OFC at birth, thin, wrinkled skin with readily visible veins, inguinal hernia,

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: Proband was noted to not have: Hyperextensibility of joints, ocular depression, Riegar anomaly, lipoatrophy, glaucoma, hyperopia, astigmatism, delayed bone age, intellectual deficiency, speech delay, diabetes, hearing loss, frequent infections, congenital heart diseases, pulmonary stenosis and ovarian cysts.

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: Whole-exome sequencing and Sanger sequencing.

      Variant: NM_181523.3:c.1960C>T (p.Gln654Ter).

      ClinVar: N/A.

      CAID: CA359884699.

      gnomAD: N/A.

      VariantEvidence: A novel de novo heterozygous nonsense mutation in the PIK3R1 gene (p. Gln654*) was found in the proband.

      WES was performed to make a clear clinical diagnose. The candidate variants were first screened by a minor allele frequency < 3% against the 1000 Genomes Project, the NHLBI exome variant server or in 50 HapMap control exomes. Then, short stature, facial abnormalities were selected as the filtering clinical symptoms to analyze the screened candidate variants. According to the guidelines recommended by the American College of Medical Genetics and Genomics, a pathogenic variant of PIK3R1 gene was identified to contribute to the patient’s conditions. Sequencing result indicated c.1960C > T of PIK3R1 gene a novel nonsense mutation, leading to the termination of protein translation (p. Gln654*), which was confirmed by sanger sequencing (Fig. 2). In addition, direct sequencing results showed the genotypes of proband’s parents were wild-type, suggesting it was a de novo mutation.

      CaseAddInfo: The height of proband’s father and mother was 168 cm and 155 cm respectively. The patient also had a healthy 20-month-old brother.

      CasePMIDs: N/A.

    1. 17-year-old female

      Case#: 17-year-old female, F, Age of Report:17 y.o., Ethnicity: Cuban descent.

      CasePresentingHPOs: HP:0001510 (Growth delay), HP:0004322 (Short stature), HP:0000696 (Delayed eruption of permanent teeth/secondary tooth eruption delay), HP:0000858 (Irregular menstruation/irregular menses), HP:0100607 (Dysmenorrhea), HP:0012384 (Rhinitis), HP:0002099 (Asthma), HP:0001025 (Urticaria), HP:0031796 (Recurrent), HP:0000403 (Recurrent otitis media), HP:0010606 (Hordeolum/hordeolums), HP:0031796 (Recurrent), HP:0012204 (Recurrent vulvovaginal candidiasis/vaginal candidiasis), HP:0032168 (Clostridium difficile colitis), HP:0004315 (Decreased circulating IgG concentration/low IgG levels), HP:0045082 (Decreased body mass index/low BMI), HP:0001382 (Joint hypermobility/hyperextensible joints), HP:0011220 (Prominent forehead), HP:0000325 (Triangular face/Facial dysmorphim Triangular shape), HP:0009765 (Low hanging columella), HP:0000219 (Thin upper lip vermilion/thin upper lip), HP:0007495 (Prematurely aged appearance/aged appearance), HP:0010976 (B lymphocytopenia/low absolute B cells), HP:0410376 (Increased proportion of naive CD8 T cells/elevated CD8 T cell),

      CaseHPOFreeText: This is a 17-year-old female of Cuban descent, born to nonconsanguineous parents at 36 weeks gestational age to an uncomplicated pregnancy. Her birth weight and length were average for gestational age (7 pounds, 18 in.). She presented with a history of growth delay, short stature, and secondary tooth eruption delay. She measured below her growth curve at 1 year of age. She had growth hormone testing which resulted normal; however, she received growth hormone therapy from 3 to 10 years of age with a good response. At that time, she underwent genetic testing for short stature; however, no genetic causes of short stature were found. She has a history of irregular menses and dysmenorrhea with work-up for possible etiologies, including polycystic ovarian syndrome (PCOS), resulting negative. She has met all developmental milestones appropriately and has normal cognition.

      She has nonallergic rhinitis, mild intermittent asthma, and acute recurrent urticaria. Her history of infections includes recurrent episodes of otitis media since she was toddler requiring placement of 3 sets of ear tubes and tonsillectomy and adenoidectomy. She has a history of recurrent hordeolums and frequent episodes of vaginal candidiasis attributed to the many courses of antibiotics she has received for her various infections. She had one episode of Clostridium difficile colitis 6 months prior to presentation to our clinic. Prior immunologic evaluation at a different institution at 9 years of age was remarkable for low IgG levels, which ranged from 435 to 511 mg/dL [ref 759–1549 mg/dL]. A skin prick test to aeroallergens resulted negative. She did not receive intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin therapy at that time.

      Her physical exam was relevant for short stature (1 percentile, z = − 2.33), low weight for age (< 1 percentile, z = − 2.69), low BMI (15 percentile), and hyperextensible joints. Her facial features were significant for a prominent forehead, triangular face, low-hanging columella, thin upper lip, and aged appearance. Given concern for immune deficiency, a complete immune evaluation was obtained. Her results revealed hypogammaglobulinemia (IgG of 610 mg/dL [ref 694–1618 mg/dL]), with IgM and IgA within the reference range. The lymphocyte subset panel revealed remarkably low absolute B cells (34 cells/μL [ref 130–800 cells/μL]) and percentage (1% [ref 9–30%]). CD4 T cells were within the reference range, and CD8 T cell counts (1091 cells/μL [ref 240–890 cells/μL]) and percentage (40% [ref 17–36%]) were elevated. She had low CD4:CD8 ratio (0.84 [ref 1.00–2.90]). Follow-up B cell panel corroborated the finding of low absolute B cells (70 cells/μL [ref 100–500 cells/μL]) and revealed increased transitional B cells (6.6% CD19 + CD27-CD21-IgM+ [ref 0.5–2.8%]) and naïve B cells (5.9% CD19 + CD27-CD21-CD38- [ref 0.3–2.3%]). ImmunoCAP IgE to aeroallergens was negative, and total IgE was 2 kU/L [ref < 114 kU/L]. Vaccine boosters to S. pneumoniae, H. influenzae, diphtheria, and tetanus were given. Subsequent titers revealed protective antibodies to S. pneumoniae, H. influenzae, and diphtheria and absent response to tetanus. Her lymphocyte mitogen proliferation showed normal lymphocyte responses to phytohaemagglutinin, concanavalin A, and pokeweed mitogen. Viral testing was not performed. At this time, the decision was made to start amoxicillin prophylaxis and monthly IVIG replacement therapy.

      After initiating treatment with IVIG, our patient did not have new episodes of ear or sinus infections. IgG levels have remained within normal limits with monthly IVIG therapy. Given the finding of a PIK3R1 pathogenic variant and its known associations with SHORT syndrome, she was referred to ophthalmology and endocrinology. Of note, she started complaining of frequent headaches, not associated with administration of IVIG. Brain and cervical spine MRI revealed a Chiari I malformation for which she is being evaluated by neurosurgery.

      CaseNotHPOs: N/A.

      CaseNotHPOFreeText: She did not have protective titers to tetanus, diphtheria, pneumococcus, or influenzae.

      CasePreviousTesting: N/A.

      CaseMethod1: N/A.

      CaseMethod2: N/A.

      CaseGenotypingMethod: Invitae primary immunodeficiency 207-gene panel was obtained.

      Variant: NM_181523.3:c.1425+1G>C (n.336+1G>C).

      ClinVar: 156009.

      CAID: CA170736.

      gnomAD: N/A.

      VariantEvidence: Results revealed a heterozygous “pathogenic variant” in PIK3R1 (c.1425 + 1G > C) with an autosomal dominant mode of inheritance in association with APDS2. This variant is a missense point mutation affecting a donor splice site in intron 11, resulting in exclusion of exon 11 (Fig. 1). Her parents are not carriers of this pathogenic variant, indicating this is a de novo mutation.

      CaseAddInfo: N/A.

      CasePMIDs: N/A.

    1. The patient was a boy aged 11 years and 2 months, with chief complaints of blackened skin color on the neck over the past 10 years.
      Case#: Patient_1, male, age 11 years and 2 months at presentation, ethnicity not reported DiseaseAssertion: The patient is asserted by the authors to have SHORT syndrome due to a heterozygous frameshift variant in PIK3R1. FamilyInfo: The patient was adopted. No family history, pedigree information, or parental testing is available. CasePresentingHPOs: HP:0008212 (Acanthosis nigricans), HP:0000834 (Insulin resistance), HP:0000365 (Hearing impairment), HP:0000517 (Elevated intraocular pressure) CaseHPOFreeText: The patient was diagnosed with insulin resistance (HOMA-IR: 14.5) and hyperinsulinemia despite normal glucose tolerance. Ophthalmological examination showed increased intraocular pressure without structural anomalies. Hearing impairment was mild and limited to the left ear. No evidence of short stature or typical craniofacial features. CaseNotHPOs: HP:0004322 (Short stature), HP:0000572 (Deeply set eyes), HP:0009806 (Dental anomalies), HP:0002622 (Joint hypermobility) CaseNotHPOFreeText: Features commonly associated with SHORT syndrome, including short stature, dental anomalies, joint hypermobility, and deeply set eyes, were not observed in this patient. CasePreviousTesting: Whole exome sequencing was performed. Two additional INSR variants were identified and discussed in Supplementary Table S1: - NM_000208.3:c.*104A>G (rs1051690), a benign 3′ UTR variant (homozygous) - NM_000208.3:c.2666G>A (p.Arg889Gln) (rs187282966), a missense variant classified as of uncertain significance. GenotypingMethod: Whole exome sequencing was used to identify the PIK3R1 frameshift variant. No family segregation analysis was performed. PreviouslyPublished: No prior article is known to contain information on the same proband. Variant: NM_181523.3:c.2008delT (p.Cys670ValfsTer3) Zygosity: Heterozygous InheritancePattern: NoInheritanceAssertion MultipleGeneVariants ClinicalStatus: Symptomatic Endocrinopathy:Reported ClinVar: Not found CAID: CA2695204517 gnomAD: Not reported in gnomAD SupplementalData: Yes, additional variants identified by WES are listed in Supplementary Table S1. Ab Deficiencies VCEP

    Tags

    Annotators

    URL

  2. Jun 2026
    1. The patient was a 33-year-old woman

      Case#: 33-year-old Chinese adult female

      DiseaseAssertion: Patient is asserted to have “SHORT syndrome due to a PIK3R1 gene variant (c.1945C > T).”

      FamilyInfo: Both parents were healthy and non-consanguineous. Her father was 167 cm tall and her mother was 160 cm tall. The patient had a younger brother, aged 29, who was 175 cm tall and weighed 60 kg.

      CasePresentingHPOs: HP:0000684, HP:0000750, HP:0040270, HP:0000855, HP:0004322, HP:0001382, HP:0000858, HP:0000558, HP:0011220, HP:0000430, HP:0000331, HP:0000233, HP:0000369, HP:0005328, HP:0007392, HP:0000963, HP:0100578, HP:0001952, HP:0000819, HP:0000147, HP:0000325

      CaseHPOFreeText: Patient has a spontaneous full-term vaginal delivery without birth trauma or asphyxia. At birth, the patient weighed 2000 g (< 3rd percentile), though her length was unknown. Her first primary tooth emerged at 9 months and her ability to say “mom” and “dad” developed at 10 months. Throughout childhood, the patient consistently lagged in growth and development compared with their peers. At 5 years of age, her height was only 99.7 cm (−3 SD) and her weight 11.5 kg(< 3rd percentile). By age 9, her height was 116.5 cm (−3 SD) and her weight was 15.0 kg(< 3rd percentile). Her test results revealed a fasting blood glucose (FBG) level of 5.48 mmol/L and 2-hour postprandial blood glucose level of 8.04 mmol/L. Notably, her postprandial 2-hour insulin level exceeded the upper detection limit (> 2152.5 pmol/L), while her postprandial 2-hour C-peptide level was 0.4 nmol/L. Her glycosylated hemoglobin (HbA1c) was 5.78%. Consequently, she was prescribed long-term voglibose monotherapy. The patient exhibited distinctive facial features. The patient also exhibited visible veins and had polycystic ovarian syndrome. Height: 147.50 cm, Weight: 37.50 kg, BMI: 17.24 kg/m2, Lean mass: 23.90 kg, Fat mass: 9.30 kg, VFA: 35.3 cm2, Total cholesterol: 4.20 mmol/L, HDL-c: 1.09 mmol/L, LDL-c: 2.92 mmol/L, Triglyceride: 1.47 mmol/L, Calcium: 2.19 mmol/L, Phosphorous: 1.25 mmol/L, 25-hydroxyvitamin D3: 14.5 ng/ml, TSH: 1.97 mIU/L, Free T4: 11.47 pmol/L, Total testosterone: 1.47 nmol/L

      CaseNotHPOs: HP:0001249, HP:0000956, HP:0002240, HP:0001397,<br /> HP:0000501, HP:0000488, HP:0009830

      CaseNotHPOFreeText: Elevated plasma triglycerides, ocular hypotension, diabetic kidney disease, lower extremity arterial disease. The patient exhibited no lipid dysregulation, with fat mass and visceral fat area falling below the normal range, accompanied by a reduction in lean body mass.

      CasePreviousTesting: NR

      GenotypingMethod: Whole-exome sequencing

      PreviouslyPublished: No

      Variant: NM_181523.3:c.1945C>T

      ClinVar: 60763

      gnomAD: NR

      SupplementalData: Table 1, 2, 3, 4

    1. 49-year-old woman

      Case#: 49-year-old woman

      DiseaseAssertion: CTLA-4 deficiency-associated GLILD

      FamilyInfo: Family history is negative for hereditary and immunological diseases

      CasePresentingHPOs: HP:0031246, HP:0033709, HP:0002094

      CaseHPOFreeText: Laboratory tests revealed decreased levels of serum globulin (IgG, IgA, and IgM) and pancytopenia. Serum soluble interleukin-2 receptor levels were elevated within the normal range for angiotensin-converting enzyme levels. Serum antibodies to human immunodeficiency virus (HIV) were within the normal CD4+ T-cell count limit at 1,079 /μL. A flow cytometric analysis demonstrated a decreased number of CD19+CD27+ memory B cells in the blood, with a selective decrease in IgG- and IgA-producing memory B cells. Chest radiography revealed bilateral infiltration of the lower lung fields while chest CT showed bilateral lower lobe reticular shadows as well as right middle lobe infiltrative and scattered nodular shadows in both the upper lobes. Bronchoalveolar lavage (BAL) showed increased cell counts (5.5×104/μL) and increased eosinophils, neutrophils, and lymphocytes in the cell fraction (eosinophils, 7%; neutrophils, 3%; lymphocytes, 25%; macrophages, 65%). The CD4/CD8 ratio in the lymphocytes was within the normal range (CD4/CD8 ratio: 1.06). A transbronchial lung biopsy revealed mild lymphocytic and eosinophilic infiltration of the cell septa. A pathological examination at low magnification revealed collapsed alveolar spaces with surrounding fibrotic changes, and at high magnification, thickened alveolar walls, nodule formation with lymphocyte and plasma cell infiltration, and lymphatic follicles were found. Polypoid plugs of loose organizing connective tissue (Masson bodies) within alveoli and small granulomas were also present. The infiltrated lymphocytes were CD3- or CD20-positive.

      CaseNotHPOFreeText: Autoantibodies also tested negative. Bacterial and mycobacterial culture for chronic lower respiratory tract infections were negative. IgG4-positive cells were not detected. There was no neutrophil accumulation or presence of fungus, Gram-positive and/or Gram-negative bacteria, or acid-fast bacteria that would have suggested infection. No findings of vasculitis or malignant tumors were noted.

      CasePreviousTesting: NR

      GenotypingMethod: NR

      PreviouslyPublished: NR

      Variant: NM_005214.5:c.160G>A

      ClinVar: 430905

      CAID: CA350138187

      gnomAD: NR

      SupplementalData: Table, Fig 1a-c, Fig 2a-f

    1. A 15-year-old girl,

      Case#: 15-year-old girl, ethnicity not specified DiseaseAssertion: The patient is asserted to have "CTLA-4 deficiency" FamilyInfo: CasePresentingHPOs: HP:0002315 (Headaches), HP:0002205 (Recurrent respiratory infections), HP:0007359 (Focal-onset seizure), HP:0001744 (Splenomegaly), HP:0002028 (Chronic diarrhea), HP:0005231 (Chronic gastritis), HP:0002875 (Exertional dyspnea), HP:0003139 (Panhypogammaglobulinemia) CaseHPOFreeText: Brain MRI showed multiple inflammatory lesions. CSF analysis showed elevated white cell count and protein levels. Figure 2 provides overview of clinical history and medical management. CaseNotHPOs: CaseNotHPOFreeText: Infectious diseases were excluded, including CMB, EBV, HIV, and mycobacteria. CasePreviousTesting: GenotypingMethod: Patient was tested via a targeted NGS panel. PreviouslyPublished: Not previously published. Variant: The patient harbors the NM_005214.5(CTLA4): c.394G>A (p.Glu132Lys) variant in the heterozygous state. ClinVar: 662200 gnomAD: This variant was not found in gnomAD v4.1.0 SupplementalData: Supplementary Table S1 contains full immunological workup.

    1. A 14-year-old adolescent girl first developed a relapsing-remitting inflammatory CNS disorder and thrombocytopenia in 1999

      Case#: The patient is a 39-year-old female with symptom onset at 14.

      DiseaseAssertion: The patient is asserted to have "CTLA-4 happloinsufficiency." "Affected patients develop cytopenia, lymphoproliferative disorders, and hypogammaglobulinemia and are prone to a variety of autoimmune phenomena."

      FamilyInfo: None provided

      CasePresentingHPOs: HP:0001873 (Thrombocytopenia), HP:0001888 (Lymphopenia), HP:0001903 (Anemia), HP:0004313 (Decreased circulating immunoglobulin concentration), HP:0002028 (Chronic diarrhea), HP:0002024 (Malabsorption), HP:0001596 (Alopecia), HP:4000055 (Intestinal inflammation), HP:0006824 (Cranial nerve paralysis), HP:0002090 (Pneumonia), HP:0001269 (Hemiparesis)

      CaseHPOFreeText: CSF analysis showed intrathecal synthesis of immunoglobulins G and M. MRI showed disseminated T2-hyperintense lesions, some lesions indicated long-lasting gadolinium enhancement (Figure 1A). PET scan-guided brain biopsy showed sustained myeline integrity, massive infiltration of T cells, and presence of few perivascular B cells. Infectious or neoplastic conditions were ruled out.

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Laboratory testing was negative for infectious or rheumatologic conditions. Brain vessel angiography was normal.

      CasePreviousTesting: None reported.

      GenotypingMethod: Sequencing of the LRBA and CTLA4 genes was performed. Authors did not elaborate on methodology or assay.

      PreviouslyPublished No prior article is known to contain information on the same proband.

      Variant: The patient is heterozygous for the NM_005214.5(CTLA4):c.322_323insT (p.Ser108MetfsTer46) variant.

      CAID: CA3270658428

      gnomAD: This variant is not found in gnomAD v4.1.1.

      SupplementalData: Figure 1A shows MRI scans from 2014-2021. Figure 1B shows immunomodulatory treatment of the patient. Figure 1C shows blood lymphocyte count and lymphocyte subsets over time. Figure 1D shows Crohn disease activity index, blood platelet count, and serum immunoglobulins. Figure 2 shows single-cell RNA sequencing of peripheral blood monocular cells.

  3. Feb 2026
  4. Aug 2025
    1. A 55-year-old male

      Case#: 55-year-old man

      DiseaseAssertion: single coronary artery (SCA) and presented with dilated cardiomyopathy (DCM)

      FamilyInfo: Unremarkable

      ParentalTesting: NR

      CasePresentingHPOs: HP:0002094, HP:0031352, HP:0001638, HP:0001644, HP:0010741

      CaseHPOFreeText: chest tightness and dyspnoea after activity lasting for 2 months. CTCA showed congenital absence of the right coronary artery. TTE revealed enlargement of the left heart and cardiomyopathy. CMR revealed DCM. oedema of both lower limbs. Laboratory data in Table 1.

      CaseNotHPOs: NR

      CaseNotHPOFreeText: Stenosis

      CasePreviousTesting: See NGS results in Supplementary Table 1

      Genotyping Method: Genetic screening (NGS results in Supplementary Table 1) with confirmation by Sanger

      FunctionalAnalysis: NR

      Variant: c.1858C>T (p.Arg620Cys)

      ClinVar: 67694

      CAID: CA015449

      gnomAD: v4.1.0 GrpMax FAF: 0.00002033 (European non-Finnish)

      AdditionalInfo: The patient also has APOA5:c.990_993delAACA (p. Asp332Valfs*5) (P/LP in ClinVar with 2 stars)